CompuGroup Medical SE KGaA Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
CompuGroup Medical SE KGaA wird ein jährliches Gewinn- und Umsatzwachstum von 31.5% bzw. 1.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 31.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.8% betragen.
Wichtige Informationen
27.5%
Wachstumsrate der Gewinne
27.4%
EPS-Wachstumsrate
| Healthcare Services Gewinnwachstum | 26.1% |
| Wachstumsrate der Einnahmen | 1.5% |
| Zukünftige Eigenkapitalrendite | 13.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 20 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 18
Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20
May 11Recent updates
Here's What's Concerning About CompuGroup Medical SE KGaA's (ETR:COP) Returns On Capital
Sep 06Here's Why CompuGroup Medical SE KGaA (ETR:COP) Has A Meaningful Debt Burden
Aug 20What You Can Learn From CompuGroup Medical SE & Co. KGaA's (ETR:COP) P/E After Its 34% Share Price Crash
Aug 04CompuGroup Medical SE & Co. KGaA (ETR:COP) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 18Is It Too Late To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?
Jul 15Investors Still Waiting For A Pull Back In CompuGroup Medical SE & Co. KGaA (ETR:COP)
Jun 11The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence
May 24Earnings Release: Here's Why Analysts Cut Their CompuGroup Medical SE & Co. KGaA (ETR:COP) Price Target To €43.20
May 11CompuGroup Medical SE KGaA (ETR:COP) Will Pay A Larger Dividend Than Last Year At €1.00
Apr 27CompuGroup Medical SE KGaA's (ETR:COP) Upcoming Dividend Will Be Larger Than Last Year's
Apr 12We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt
Mar 20CompuGroup Medical SE & Co. KGaA (ETR:COP) Shares Could Be 49% Below Their Intrinsic Value Estimate
Feb 08Investors Interested In CompuGroup Medical SE & Co. KGaA's (ETR:COP) Earnings
Jan 25Is It Time To Consider Buying CompuGroup Medical SE & Co. KGaA (ETR:COP)?
Jan 12The Returns On Capital At CompuGroup Medical SE KGaA (ETR:COP) Don't Inspire Confidence
Dec 28We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt
Dec 15Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Potentially Undervalued?
Oct 09CompuGroup Medical SE KGaA (ETR:COP) Could Be Struggling To Allocate Capital
Sep 22Do CompuGroup Medical SE KGaA's (ETR:COP) Earnings Warrant Your Attention?
Sep 07Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Trading At A 33% Discount?
Aug 23Here's Why CompuGroup Medical SE KGaA (ETR:COP) Can Manage Its Debt Responsibly
Jul 13At €46.82, Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Worth Looking At Closely?
Jun 24CompuGroup Medical SE KGaA (ETR:COP) Is Reinvesting At Lower Rates Of Return
May 27CompuGroup Medical SE KGaA (ETR:COP) Has Announced A Dividend Of €0.50
May 11Is CompuGroup Medical SE & Co. KGaA (ETR:COP) Trading At A 32% Discount?
May 06We Think CompuGroup Medical SE KGaA (ETR:COP) Can Stay On Top Of Its Debt
Apr 06What Does CompuGroup Medical SE & Co. KGaA's (ETR:COP) Share Price Indicate?
Mar 07Be Wary Of CompuGroup Medical SE KGaA (ETR:COP) And Its Returns On Capital
Feb 06An Intrinsic Calculation For CompuGroup Medical SE & Co. KGaA (ETR:COP) Suggests It's 28% Undervalued
Jan 21These 4 Measures Indicate That CompuGroup Medical SE KGaA (ETR:COP) Is Using Debt Reasonably Well
Jan 05Is Now An Opportune Moment To Examine CompuGroup Medical SE & Co. KGaA (ETR:COP)?
Dec 06CompuGroup Medical SE KGaA (ETR:COP) May Have Issues Allocating Its Capital
Oct 27Are Investors Undervaluing CompuGroup Medical SE & Co. KGaA (ETR:COP) By 49%?
Oct 12At €39.20, Is It Time To Put CompuGroup Medical SE & Co. KGaA (ETR:COP) On Your Watch List?
Sep 04CompuGroup Medical SE KGaA (ETR:COP) Has A Pretty Healthy Balance Sheet
Aug 04Here's What's Concerning About CompuGroup Medical SE KGaA's (ETR:COP) Returns On Capital
Jul 16When Should You Buy CompuGroup Medical SE & Co. KGaA (ETR:COP)?
May 31CompuGroup Medical SE KGaA (ETR:COP) Has Announced A Dividend Of €0.50
May 11Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,248 | 76 | 95 | 195 | 9 |
| 12/31/2025 | 1,209 | 66 | 80 | 180 | 9 |
| 12/31/2024 | 1,171 | 56 | 42 | 145 | 9 |
| 6/30/2024 | 1,193 | 32 | 68 | 138 | N/A |
| 3/31/2024 | 1,220 | 50 | 93 | 162 | N/A |
| 12/31/2023 | 1,228 | 46 | 112 | 180 | N/A |
| 9/30/2023 | 1,247 | 76 | 135 | 201 | N/A |
| 6/30/2023 | 1,249 | 89 | 123 | 193 | N/A |
| 3/31/2023 | 1,214 | 70 | 82 | 157 | N/A |
| 12/31/2022 | 1,175 | 73 | 69 | 145 | N/A |
| 9/30/2022 | 1,127 | 72 | 45 | 122 | N/A |
| 6/30/2022 | 1,116 | 71 | 58 | 140 | N/A |
| 3/31/2022 | 1,088 | 76 | 88 | 165 | N/A |
| 12/31/2021 | 1,063 | 69 | 94 | 165 | N/A |
| 9/30/2021 | 1,021 | 66 | 88 | 155 | N/A |
| 6/30/2021 | 975 | 72 | 111 | 166 | N/A |
| 3/31/2021 | 915 | 71 | 113 | 168 | N/A |
| 12/31/2020 | 869 | 73 | 94 | 150 | N/A |
| 9/30/2020 | 833 | 77 | 86 | 128 | N/A |
| 6/30/2020 | 779 | 60 | 34 | 80 | N/A |
| 3/31/2020 | 781 | 58 | 60 | 107 | N/A |
| 12/31/2019 | 770 | 66 | 67 | 110 | N/A |
| 9/30/2019 | 757 | 87 | 83 | 137 | N/A |
| 6/30/2019 | 742 | 86 | 123 | 170 | N/A |
| 3/31/2019 | 747 | 97 | 109 | 155 | N/A |
| 12/31/2018 | 736 | 96 | 97 | 136 | N/A |
| 9/30/2018 | 707 | 65 | 73 | 112 | N/A |
| 6/30/2018 | 678 | 52 | 64 | 109 | N/A |
| 3/31/2018 | 624 | 39 | N/A | 101 | N/A |
| 12/31/2017 | 599 | 31 | N/A | 86 | N/A |
| 9/30/2017 | 586 | 41 | N/A | 89 | N/A |
| 6/30/2017 | 583 | 46 | N/A | 80 | N/A |
| 3/31/2017 | 578 | 47 | N/A | 78 | N/A |
| 12/31/2016 | 571 | 45 | N/A | 68 | N/A |
| 9/30/2016 | 562 | 41 | N/A | 67 | N/A |
| 6/30/2016 | 553 | 36 | N/A | 68 | N/A |
| 3/31/2016 | 556 | 27 | N/A | 55 | N/A |
| 12/31/2015 | 553 | 38 | N/A | 73 | N/A |
| 9/30/2015 | 548 | 34 | N/A | 41 | N/A |
| 6/30/2015 | 547 | 40 | N/A | 31 | N/A |
| 3/31/2015 | 535 | 42 | N/A | 35 | N/A |
| 12/31/2014 | 525 | 26 | N/A | 32 | N/A |
| 9/30/2014 | 511 | 29 | N/A | 55 | N/A |
| 6/30/2014 | 496 | 24 | N/A | 51 | N/A |
| 3/31/2014 | 479 | 18 | N/A | 45 | N/A |
| 12/31/2013 | 470 | 24 | N/A | 52 | N/A |
| 9/30/2013 | 462 | 19 | N/A | 50 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: COPDas prognostizierte Gewinnwachstum (31.5% pro Jahr) liegt über der Sparquote (0.8%).
Ertrag vs. Markt: COPDie Erträge des Unternehmens (31.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (20% pro Jahr).
Hohe Wachstumserträge: COPEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: COPDie Einnahmen des Unternehmens (1.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt German (5.2% pro Jahr).
Hohe Wachstumseinnahmen: COPDie Einnahmen des Unternehmens (1.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: COPDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.8%).